This model seems to be in agreement with recent reports showing that FOXM1 sensitizes tumor cells to Chk1 and WEE1 inhibitors (Chung et al., 2019; Branigan et al., 2021; Diab et al., 2020). Here, FOXM1 is linked to neoplasm.